Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension

Annals of the Rheumatic Diseases

Volumn 76, Issue 11, 2017, Pages 1931-1940

  Avouac, Jerome ^a   Konstantinova, Irena ^b   Guignabert, Christophe ^c,d   Pezet, Sonia ^a   Sadoine, Jeremy ^e   Guilbert, Thomas ^a   Cauvet, Anne ^a   Tu, Ly ^c,d   Luccarini, Jean Michel ^b   Junien, Jean Louis ^b   Broqua, Pierre ^b   Allanore, Yannick ^a,e  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Inventiva   (France)

^c Universite Paris Sud   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e and Plateforme d'Imagerie du Vivant   (France)

Author keywords

IVA337; nuclear receptors; PPAR.; pulmonary fibrosis; pulmonary hypertension; systemic sclerosis

Indexed keywords

HYDROXYPROLINE; LANIFIBRANOR; TRANSFORMING GROWTH FACTOR BETA; BENZOTHIAZOLE DERIVATIVE; BLEOMYCIN; FOSL2 PROTEIN, MOUSE; SULFONAMIDE; TRANSCRIPTION FACTOR FRA 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL PULMONARY FIBROSIS; EXPERIMENTAL PULMONARY HYPERTENSION; HUMAN; HUMAN CELL; LUNG FIBROBLAST; LUNG HEMODYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RECEPTOR BLOCKING; VASCULAR REMODELING; AGONISTS; ANIMAL; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; FIBROBLAST; HYPERTENSION, PULMONARY; MYOFIBROBLAST; PHYSIOLOGY; PULMONARY ARTERY; PULMONARY FIBROSIS; SEVERITY OF ILLNESS INDEX; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ANIMALS; BENZOTHIAZOLES; BLEOMYCIN; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FIBROBLASTS; FOS-RELATED ANTIGEN-2; HYPERTENSION, PULMONARY; MICE; MICE, TRANSGENIC; MYOFIBROBLASTS; PULMONARY ARTERY; PULMONARY FIBROSIS; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; VASCULAR REMODELING;

EID: 85030998816     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210821     Document Type: Article

References (36)

1. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210.
2. P alumbo-Zerr K, Zerr P, Distler A, et al. Orphan nuclear receptor NR4A1 regulates transforming growth factor-â signaling and fibrosis. Nat Med 2015;21:150-8.
3. R uzehaji N, Frantz C, Ponsoye M, et al. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. Ann Rheum Dis 2016;75:2175-83.
4. Ghosh AK, Bhattacharyya S, Wei J, et al. Peroxisome proliferator-Activated receptorgamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. Faseb J 2009;23:2968-77.
5. Samah M, El-Aidy A-R, Tawfik MK, et al. Evaluation of the antifibrotic effect of fenofibrate and rosiglitazone on bleomycin-induced pulmonary fibrosis in rats. Eur J Pharmacol 2012;689(1-3):186-93.
6. Aoki Y, Maeno T, Aoyagi K, et al. Pioglitazone, a peroxisome proliferator-Activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis. Respiration 2009;77:311-9.
7. Galuppo M, Di Paola R, Mazzon E, et al. GW0742, a high affinity PPAR-â/ä agonist reduces lung inflammation induced by bleomycin instillation in mice. Int J Immunopathol Pharmacol 2010;23:1033-46.
8. Sutliff RL, Kang BY, Hart CM. PPARgamma as a potential therapeutic target in pulmonary hypertension. Ther Adv Respir Dis 2010;4:143-60.
9. Wettstein G, Estivalet C, Tessier J, et al. The New Generation Pan-Ppar agonist Iva337 protects the liver from metabolic disorders and fibrosis. J Hepatol 2016;64:S169-S170.
10. Herzog EL, Mathur A, Tager AM, et al. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol 2014;66:1967-78.
11. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the diagnosis and treatment of pulmonary hypertension of the european Society of Cardiology (ESC) and the european respiratory society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and lung transplantation (ISHLT). Eur Respir J 2015;46:903-75.
12. Humbert M, Sitbon O, Yaïci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010;36:549-55.
13. Humbert M, Lau EM, Montani D, et al. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation 2014;130:2189-208.
14. Avouac J, Elhai M, Tomcik M, et al. Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammationdriven dermal fibrosis in a mouse model of systemic sclerosis. Ann Rheum Dis 2013;72:1089-98.
15. P onsoye M, Frantz C, Ruzehaji N, et al. Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammationdriven fibrosis. Ann Rheum Dis 2016;75:2142-9.
16. Elhai M, Avouac J, Hoffmann-Vold AM, et al. OX40L blockade protects against inflammation-driven fibrosis. Proc Natl Acad Sci U S A 2016;113:E3901-E3910.
17. Guignabert C, Alvira CM, Alastalo TP, et al. Tie2-mediated loss of peroxisome proliferator-Activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization. Am J Physiol Lung Cell Mol Physiol 2009;297:L10 82-L1090.
18. R icard N, Tu L, Le Hiress M, et al. Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension. Circulation 2014;129:1586-97.
19. Huertas A, Tu L, Thuillet R, et al. Leptin signalling system as a target for pulmonary arterial hypertension therapy. Eur Respir J 2015;45:1066-80.
20. Le Hiress M, Tu L, Ricard N, et al. Proinflammatory signature of the Dysfunctional Endothelium in pulmonary hypertension. role of the macrophage migration inhibitory factor/CD74 complex. Am J Respir Crit Care Med 2015;192:983-97.
21. Choi EJ, Jin GY, Bok SM, et al. Serial micro-CT assessment of the therapeutic effects of rosiglitazone in a bleomycin-induced lung fibrosis mouse model. Korean J Radiol 2014;15:448-55.
22. Genovese T, Cuzzocrea S, Di Paola R, et al. Effect of rosiglitazone and 15-deoxy-Delta12, 14-prostaglandin J2 on bleomycin-induced lung injury. Eur Respir J 2005;25:225-34.
23. Arora MK, Reddy K, Balakumar P. The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy. Eur J Pharmacol 2010;636(1-3):137-44.
24. Maurer B, Busch N, Jöngel A, et al. Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation 2009;120:2367-76.
25. Luther J, Ubieta K, Hannemann N, et al. Fra-2/AP-1 controls adipocyte differentiation and survival by regulating pparã and hypoxia. Cell Death Differ 2014;21:655-64.
26. Maurer B, Reich N, Juengel A, et al. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis 2012;71:1382-7.
27. Standiford TJ, Keshamouni VG, Reddy RC. Peroxisome proliferator-Activated receptor-{gamma} as a regulator of lung inflammation and repair. Proc Am Thorac Soc 2005;2:226-31.
28. Ward JE, Gould H, Harris T, et al. PPAR gamma ligands, 15-deoxy-delta12, 14-prostaglandin J2 and rosiglitazone regulate human cultured airway smooth muscle proliferation through different mechanisms. Br J Pharmacol 2004;141:517-25.
29. Keshamouni VG, Reddy RC, Arenberg DA, et al. Peroxisome proliferator-Activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 2004;23:100-8.
30. Lin Q, Fang LP, Zhou WW, et al. Rosiglitazone inhibits migration, proliferation, and phenotypic differentiation in cultured human lung fibroblasts. Exp Lung Res 2010;36:120-8.
31. Milam JE, Keshamouni VG, Phan SH, et al. PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008;294:L891-L901.
32. T akahashi F, Takahashi K, Okazaki T, et al. Role of osteopontin in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2001;24:264-71.
33. Manoury B, Caulet-Maugendre S, Guénon I, et al. TIMP-1 is a key factor of fibrogenic response to bleomycin in mouse lung. Int J Immunopathol Pharmacol 2006;19:471-87.
34. Hart CM, Roman J, Reddy R, et al. PPARgamma: A novel molecular target in lung disease. J Investig Med 2008;56:515-7.
35. N isbet RE, Sutliff RL, Hart CM. The role of peroxisome proliferator-Activated receptors in pulmonary vascular disease. PPAR Res 2007;2007:1-10.
36. Lamé MW, Jones AD, Wilson DW, et al. Protein targets of monocrotaline pyrrole in pulmonary artery endothelial cells. J Biol Chem 2000;275:29091-9.